DE version is available. Content is displayed in original English for accuracy.
I’m Lloyd, one of two founders of RonanRx. We are building a vertically integrated pharmaceutical company with software for prescribing, telehealth, compounding, manufacturing, and delivery. We are starting with GLP-1s and peptides.
The path to RonanRx is fairly unconventional. During the pandemic, I built one of the largest mask manufacturing factories in the US. We could make a million masks in a day. We converted raw polypropylene pellets into finished pallets of masks.
I had a background in software from my YC W10 company, so we took a software approach to building our factory. We used machine learning and computer vision to optimize production. We also vertically integrated almost everything. It worked. We built an efficient manufacturing operation and grew the business to 50 million dollars in revenue. Then people actually stopped caring about masks. Fair enough.
Around the same time, I decided to try and lose the weight I had gained while building the factory. I ate nothing but chicken for six months. While this diet got some results, I plateaued. My doctor suggested tirzepatide, a GLP-1 medication.
For me, losing weight was only the beginning. "Food noise" was gone. I showed less interest in other compulsive behavior. I stopped scrolling Instagram and quit biting my nails. But that was just the beginning. I was born with a congenital heart defect called aortic stenosis. My whole life doctors told me I'd need open heart surgery in my 40s (I am 45 now). After just 18 months using tirzepatide, my cardiologist’s began to think (and still thinks) my surgery could be pushed back until I am 70 or 80.
This was all happening when I was deciding what to work on next. I wanted to keep working on manufacturing. I didn't want to build another product that could be replicated by a frontier model. Pharmaceutical manufacturing was the best combination of digital, physical, biological, and regulatory infrastructure I could find. The thing that bothered me was how disconnected all of the pieces were: telehealth, EHR, prescriptions, dispensing software, production, shipping. No one company has it all.
GLP-1s come in a handful of predefined doses, but patients obviously aren't standardized: they respond differently, lose weight at different rates, experience different side effects, and may need very different doses. Compounding pharmacies can fill customized prescriptions, but they are not built like software companies. Workflows are manual, fragmented, and disconnected from the patient’s data. It's our goal to connect those pieces with RonanRx.
Patients either come to us directly or are referred by a physician. Once a patient is in our system, we collect medical records, current meds, labs, and data from wearables. Our software follows the prescription through drug formulation, compounding, quality testing, and drug dispensing and distribution.
The most interesting feature is the feedback loop. As the patient is undergoing treatment, their response becomes data that can be used by their doctor to modify the treatment. We keep the doctor in the feedback loop.
We make money by selling drugs we manufacture. Because people can buy directly from us, their price is usually 3x-10x more affordable. We can do this because we start at the molecule and own the entire stack from manufacturing through prescribing, dispensing, and delivery, instead of paying a chain of middlemen at every step.
We are beginning with GLP-1s and peptides since this was where I personally experienced the issue; however, we are more interested in the potential of patient-specific pharmaceutical manufacturing.
We would love your feedback, especially if you have built pharmacy, manufacturing, clinical infrastructure, EHRs, or any other regulated software. There are a lot of assumptions in this model that should be tested.
Discussion (18 Comments)Read Original on HackerNews
At the same time, nothing is stopping you from hiring a fractional medical director and doctors alongside NP. I ran the numbers and 50k is is all you need to get a service agreement with a compounding pharmacy, back office tasks, incorporation, social media marketing policy to essentially drop ship your product as you use off the shelf products for charting and then begin expanding state coverage.
The July Medicare glp1 coverage also makes this most opportune.
Biggest barrier I thought was / is the credit card processing. You need to carry a certification for that.
HIPAA not an issue, BAA with most orgs that offer a saas products.
So damn. The glue isn’t really hard. Really didn’t think this would qualify as an ycombinator mvp. But here I am used To pitch decks promising exponential growth of subscription for cloud services.
As for personalized peptides in general, are you going to be marketing non FDA approved ones?
Or just stick with what’s already popular, generic wegovy, zepbound, etc. the market seems highly thin as a new MSO appears everyday using smartiq alongside med spas that offer more questionable inpatient services.
While manufacturing controls supply chain / logistics, the external pressure from every compounding pharmacist scaling into peptides now makes me wonder the longevity abo it this. You can literally pop on subreddits and see the flavor of the month telemedicine practice offer teaser rates of $99 for 60mg/month tirezepatide.
Oh and not forgetting the elephant in the room, gray market and china manufacturing which allows anyone with a telegram account to directly order whatever chemical name they read with no doctor oversight. It’s what, sub $1/mg now from the major vendors for tirezepatide?
I've led building an EHR totally from scratch at one company and currently advising another as they build their EHR, both totally integrated approaches in industries where you usually have lots of disconnected care (adolescent serious mental illness and ABA/autism care). The state-by-state regulatory challenges are very real! If you want to chat, my email is in my profile!
BTW: when you say you manufacture the drugs, I assume that means you're buying from an API supplier, but do you actually mean you're synthesizing it yourself?
The legal cutout that we have is on the personalization front, which is very well protected. The trick is that most compounders are not actually personalizing, and we are. Our feedback loop allows us to do real personalization on a week-by-week basis.
Your website sucks though. We can tell you vibe coded it quickly and didn't put much thought into it.
These messages are very helpful, though, to help motivate me to get our team to fix this, so I do appreciate it.